Ferran Prat Escude

While we still collect presentation details, it's exciting to have the expansive Phacilitate Advanced Therapies Week agenda up for the January 2025 meeting. We're excited to hit the ground running in 2025 and showcase the technical prowess and novel programs in cell and gene therapies. Don't miss out on our: - 🌟 Advanced Therapies Investment Summit, being built by Serena Mirpuri - 🌟 Women in Advanced Therapies Congress, led by Becky Johnson-Kent & Serena Mirpuri - 🌟 Advanced Therapies Awards 6 core tracks, including: - 🌟 Therapeutic Advances - 🌟 Commercializing Future Therapies - 🌟 Gene Therapy Manufacturing - 🌟 Cell Therapy Manufacturing - 🌟 CGT Supply Chain - 🌟 Patient Considerations and Advocacy Not to mention our stellar Innovation Showcase, placing early-stage companies in front of potential investors and partners (Reach out to Cameron Binns if you want to join!) There are still sponsor opportunities across the agenda and show floor, so reach out to David Green, Ayaan Lowry & Becky Johnson-Kent for opportunities (including our new 30-minute briefing format!) If you are a speaker/panelist or sponsor and need any modifications to your agenda segment, reach out directly to myself (Ry Leahy) and Serena Mirpuri! I'm very excited to see you in Dallas this January, and look forward to our conversations about the future of our exciting field. #ATW25 #AdvancedTherapiesWeek #Phacilitate #AdvancedTherapies #Cellandgenetherapy #celltherapy #genetherapy #regenerativemedicine #biotech #biotechnology #lifesciences #genetics

11

We've advanced to the next planned cohort of our Phase 1B ADVENT-AML trial of CHM CORE-NK. The trial, conducted at The University of Texas MD Anderson Cancer Center, aims to evaluate the synergy of NK cell therapy in combination with the current standard of care for acute myeloid leukemia (AML). In the first cohort, three patients received CHM CORE-NK alongside standard treatment without experiencing dose-limiting toxicities. Now, the trial moves to the second cohort, testing a higher dose of CHM CORE-NK in combination with aza/ven. The study plans to enrol up to 20 newly diagnosed AML patients who are not eligible for intensive chemotherapy or stem cell transplant. Chief Operating Officer Dr Rebecca McQualter commented, “It has been great to see the progress of this clinical trial for these AML patients." Read the full ASX Announcement here: https://lnkd.in/g4883Gtn #ADVENTAML #ChimericTherapeutics #CHM #NKcellTherapy #CancerTrial #AMLResearch #ClinicalTrial #CancerTherapy #ASX #ASXNews #biotech 

46

🚀 Exciting Clinical Milestone for Eisbach Bio! 🚀 We are thrilled to announce that the first patient has been dosed in our Phase 1/2 MATCH clinical trial of EIS-12656. The cancer trial conducted at The University of Texas MD Anderson Cancer Center, marks a significant step forward in our mission to develop transformative medicines leveraging synthetic lethality. “Our entry into the cancer clinic with the allosteric inhibitor EIS-12656 represents a unique approach in targeting ALC1, offering hope for patients with tumors characterized by impaired DNA damage and repair,” said Adrian Schomburg, Ph.D., Founder and CEO of Eisbach Bio GmbH. “This clinical study will explore EIS-12656’s potential to target specific genetic and molecular vulnerabilities, aiming to deliver a drug that is both efficacious and well-tolerated.” Full press release: https://lnkd.in/eTC65FeW Stay tuned for more updates as we continue our journey to pioneer the frontiers of cancer therapy. 💪 #CancerResearch #ClinicalTrials #Biotechnology #Oncology #SyntheticLethality

408

32 Comments

#MovingMedicineForward: Congratulations to our friends at #EisbachBio on dosing the first patient in their Phase 1/2 MATCH clinical trial for EIS-12656, a new allosteric inhibitor targeting genetically-defined advanced solid tumors. This study aims to evaluate the safety, tolerability, & efficacy of EIS-12656, with a focus on #Gynecological, #Pancreatic, & #Prostate cancer patients progressing under PARP inhibitor treatment. At CTI, we're proud to collaborate with Eisbach Bio in providing #Regulatory & #ClinicalTrial management services for this #Oncology trial. Together, we’re #AdvancingHealthcareSolutions for those battling advanced cancers. Learn more about this trial in the link below. 

20

It’s encouraging to see the groundbreaking work being done by OncoNano, a clinical-stage company in the Dallas-Fort Worth area, that is revolutionizing cancer treatment with nanotechnology. OncoNano's innovative approach centers on a unique polymer that self-assembles and releases its payload precisely where it's needed. This technology targets the Achilles heel of cancer: anabolic metabolism. By focusing on the highly acidic environment around tumors, OncoNano's pH-sensitive polymers form micelles—tiny structures smaller than the wavelength of visible light—that locate tumors and release therapeutic agents directly at the site. This represents a significant leap forward in cancer treatment. As the company continues to harness the power of nanotechnology to develop new therapies, there is renewed hope for more effective cancer treatments and better outcomes for patients. #CancerTreatment #Nanotechnology #Biotech #bsAbs

3

We will present two sets of data at the upcoming AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation, November 13-16, 2024, San Diego, California. 1. A cost-effective two-step approach for multi-cancer early detection in general population. 2. A Blood-Based Multi-Omics Test for Early Evaluation of Lymphoma Treatment Effectiveness.

30

More insights into our understanding of molecular mechanisms regulating the differentiation and function of human Tfr cells.

20

#ICYMI: Last month we announced that we raised $132.5 million in an oversubscribed #SeriesC financing to advance our pipeline of potential therapies for fibrotic lung diseases and oncology. We are thankful for the support of our investors, board, #biotech community and the entire Endeavor BioMedicines team.     In this BioSpace article, get more details about what this financing means for the future of our pipeline and our goal to restore hope for patients with life-threatening diseases: https://bit.ly/4aVqAmo    #biotechnews #fundraising #venturecapital #oncology #lungdiseases

51

The GW Technology Commercialization Office is pleased to share recent developments in cancer research.  Avstera Therapeutics Corp., a GW licensee, has recently published groundbreaking research on their HDAC6 inhibitor AVS100 (SS208), titled "The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy." Leveraging GW’s licensed technology, Avstera has made remarkable strides in immuno therapy.  Read more about their research and clinical developments: https://lnkd.in/e5QccFzX.  Avstera’s innovative approach, combining HDAC6 inhibition with anti-PD-1 therapy, has demonstrated significant antitumoral effects in melanoma and colon cancer models. We are proud to see our innovation driving progress in the fight against cancer, and we extend our congratulations to Avstera Therapeutics for this major milestone. #GWU #TCO #TechTransfer #Oncology #HDAC6Inhibitor #Immunotherapy #CancerResearch 

3

StevenDouglas has placed: 5 SVP's of CMC & Tech Ops 5 VP's of CMC & Tech Ops 5 Senior Directors of CMC 6 Directors of CMC (we are modality/function agnostic) Small molecule, large molecule/biologics/monoclonal antibodies, cell therapy, gene therapy, peptides/oligonucleotides, process development, analytical development & quality control, drug substance, drug product, supply chain 5 Directors of Sales (individual contributors/hunters/new business development) Our success can only follow YOUR success! September and October are historically very busy months for hiring in the biopharma domain - If we can be of assistance please reach out. WhyStevenDouglas? - It's all about YOU - YOU come first - We seek first to understand and our end-game goal/charter/credo is to help YOU far exceed YOUR hopes, wishes, ambitions, goals, and dreams by delivering top 1% talent which enables significant internal stakeholder and exponential external shareholder value! #WorkIsTheAnswer #OurCollarsAreBlue #Speed-OurLast5Placements=LessThan45DaysStartToFinish #CompleteMarketCoverage #100%KnowBeforeYouGo

7

Read Do Kim's weekly biopharma highlights including, LBPH's acquisition boosting comps like PRAX and JAZZ, WVE proving RNA editing potential, and EXEL winning a patent case. Other notable news includes positive data from JSPR, MGTX, and AURA in various therapies, while NVAX faced a COVID-flu vaccine clinical hold, and GILD withdrew its bladder cancer approval. Read the full report for more! #Biopharma #MNA #ClinicalData #RNAEditing #GeneTherapy #CancerResearch #DrugDevelopment #WTR #WaterTowerResearch https://lnkd.in/eq7Uqz7p

8

Review and perspectives Engineering strategies to safely drive CAR T-cells into the future Chimeric antigen receptor (CAR) T-cell therapy has proven a breakthrough in cancer treatment in the last decade, giving unprecedented results against hematological malignancies. All approved CAR T-cell products, as well as many being assessed in clinical trials, are generated using viral vectors to deploy the exogenous genetic material into T-cells. Viral vectors have a long-standing clinical history in gene delivery, and thus underwent iterations of optimization to improve their efficiency and safety. Nonetheless, their capacity to integrate semi-randomly into the host genome makes them potentially oncogenic via insertional mutagenesis and dysregulation of key cellular genes. Secondary cancers following CAR T-cell administration appear to be a rare adverse event. However several cases documented in the last few years put the spotlight on this issue, which might have been underestimated so far, given the relatively recent deployment of CAR T-cell therapies. Furthermore, the initial successes obtained in hematological malignancies have not yet been replicated in solid tumors. It is now clear that further enhancements are needed to allow CAR T-cells to increase long-term persistence, overcome exhaustion and cope with the immunosuppressive tumor microenvironment. To this aim, a variety of genomic engineering strategies are under evaluation, most relying on CRISPR/Cas9 or other gene editing technologies. These approaches are liable to introduce unintended, irreversible genomic alterations in the product cells. In the first part of this review, we will discuss the viral and non-viral approaches used for the generation of CAR T-cells, whereas in the second part we will focus on gene editing and non-gene editing T-cell engineering, with particular regard to advantages, limitations, and safety. Finally, we will critically analyze the different gene deployment and genomic engineering combinations, delineating strategies with a superior safety profile for the production of next-generation CAR T-cell. https://lnkd.in/gY5eEYfb

113

This article discusses sustained-delivery tyrosine kinase inhibitors currently in clinical trials and explores their potential as innovative treatment options for nAMD and DME. https://lnkd.in/eQv_9AgM

10

I hope you can join me and Lindsey Gasparini, of NeoGenomics, for a discussion of how biomarker-linked, multi-modal, longitudinal clinical datasets can be the basis for meaningful and actionable clinical insights, foundation for advanced AI model development, and inform the design of retrospective RWD and prospective RCT studies. It will be a pleasure to do this with our wonderful colleagues at Datavant (we've worked with them since our founding!) and our wonderful moderator Alan Ma. #concertai #neogenomics #precisiononcology #AI #precisionmedicine

62

Join Tim Looney from Quest Diagnostics to learn how next-generation sequencing of rearranged BCR IGH chains (BCR-seq) can provide exceptional resolution of the human B-cell repertoire. Watch now on-demand. #thermofisheremp

7

Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers Interleukin-15 (IL-15) promotes the survival of T lymphocytes and enhances the antitumour properties of chimeric antigen receptor (CAR) T cells in preclinical models of solid neoplasms in which CAR T cells have limited efficacy1,2,3,4. Glypican-3 (GPC3) is expressed in a group of solid cancers5,6,7,8,9,10, and here we report the evaluation in humans of the effects of IL-15 co-expression on GPC3-expressing CAR T cells (hereafter GPC3 CAR T cells). Cohort 1 patients (NCT02905188 and NCT02932956) received GPC3 CAR T cells, which were safe but produced no objective antitumour responses and reached peak expansion at 2 weeks. Cohort 2 patients (NCT05103631 and NCT04377932) received GPC3 CAR T cells that co-expressed IL-15 (15.CAR), which mediated significantly increased cell expansion and induced a disease control rate of 66% and antitumour response rate of 33%. Infusion of 15.CAR T cells was associated with increased incidence of cytokine release syndrome, which was controlled with IL-1/IL-6 blockade or rapidly ameliorated by activation of the inducible caspase 9 safety switch. Compared with non-responders, tumour-infiltrating 15.CAR T cells from responders showed repression of SWI/SNF epigenetic regulators and upregulation of FOS and JUN family members, as well as of genes related to type I interferon signalling. https://lnkd.in/eNtaGQ-T

57

Come visit us in Boston next week! Empowered with relative affinity analysis as you conduct series of binding / blocking assays on the Beacon, it can be your workhorse for not just difficult antigen, but every-use antigen with much more accelerated pace. Any antigen, any species, most detailed functional screening of antibodies. Antibody discovery. Autoimmune autoantibody discovery. Vaccine development from patient samples. Who doesn’t need a good antibody? Try #Beacon optofluidic technology. Exquisite control, deepest insight.

19